Zynerba Pharmaceuticals (NASDAQ:ZYNE) Upgraded to “Strong-Buy” by BidaskClub

Zynerba Pharmaceuticals (NASDAQ:ZYNE) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report released on Saturday, May 18th, BidAskClub reports.

A number of other research analysts have also weighed in on the stock. ValuEngine raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 17th. Zacks Investment Research downgraded Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $26.00 target price on shares of Zynerba Pharmaceuticals in a research report on Monday, May 6th. Roth Capital started coverage on Zynerba Pharmaceuticals in a research report on Tuesday, April 30th. They set a “buy” rating and a $36.00 target price for the company. Finally, Canaccord

... read more at: https://techknowbits.com/2019/06/11/bidaskclub-upgrades-zynerba-pharmaceuticals-zyne-to-strong-buy.html